Oncology

Enzalutamide combined with leuprolide significantly enhances survival in high-risk non-metastatic prostate cancer, marking a breakthrough in treatment strategies.

Research reveals HER2-negative breast cancer shows higher pCR rates than HER2-low, influencing neoadjuvant chemotherapy strategies for early-stage patients.

Research reveals that higher BMI in women with cardiovascular disease significantly increases breast cancer risk, highlighting the need for targeted prevention strategies.

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for zanubrutinib.

The data highlight novel therapies and biomarkers shaping personalized cancer care.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.

Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Andrew E. Esch, MD, MBA, discusses the need for systemic reforms to support pharmacist-led medication optimization in palliative and community-based care.

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.

Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.

The data revealed that only 75% of patients receive HER2-targeting therapies.

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.